Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

The BRCA2 mutation status shapes the immune phenotype of prostate cancer.

Jenzer M, Keß P, Nientiedt C, Endris V, Kippenberger M, Leichsenring J, Stögbauer F, Haimes J, Mishkin S, Kudlow B, Kaczorowski A, Zschäbitz S, Volckmar AL, Sültmann H, Jäger D, Duensing A, Schirmacher P, Hohenfellner M, Grüllich C, Stenzinger A, Duensing S.

Cancer Immunol Immunother. 2019 Sep 23. doi: 10.1007/s00262-019-02393-x. [Epub ahead of print]

PMID:
31549213
2.

An App to Improve Eating Habits of Adolescents and Young Adults (Challenge to Go): Systematic Development of a Theory-Based and Target Group-Adapted Mobile App Intervention.

Rohde A, Duensing A, Dawczynski C, Godemann J, Lorkowski S, Brombach C.

JMIR Mhealth Uhealth. 2019 Aug 12;7(8):e11575. doi: 10.2196/11575.

3.

Genomic aberrations in cell cycle genes predict progression of KIT-mutant gastrointestinal stromal tumors (GISTs).

Heinrich MC, Patterson J, Beadling C, Wang Y, Debiec-Rychter M, Dewaele B, Corless CL, Duensing A, Raut CP, Rubin B, Ordog T, van de Rijn M, Call J, Mühlenberg T, Fletcher JA, Bauer S.

Clin Sarcoma Res. 2019 Mar 5;9:3. doi: 10.1186/s13569-019-0112-7. eCollection 2019.

4.

Green Methodologies for Copper(I)-Catalyzed Azide-Alkyne Cycloadditions: A Comparative Study.

Trujillo M, Hull-Crew C, Outlaw A, Stewart K, Taylor L, George L, Duensing A, Tracey B, Schoffstall A.

Molecules. 2019 Mar 10;24(5). pii: E973. doi: 10.3390/molecules24050973.

5.

Cullin 5 is a novel candidate tumor suppressor in renal cell carcinoma involved in the maintenance of genome stability.

Tapia-Laliena MÁ, Korzeniewski N, Peña-Llopis S, Scholl C, Fröhling S, Hohenfellner M, Duensing A, Duensing S.

Oncogenesis. 2019 Jan 9;8(1):4. doi: 10.1038/s41389-018-0110-2.

6.

Correlation between genomic index lesions and mpMRI and 68Ga-PSMA-PET/CT imaging features in primary prostate cancer.

Kesch C, Radtke JP, Wintsche A, Wiesenfarth M, Luttje M, Gasch C, Dieffenbacher S, Pecqueux C, Teber D, Hatiboglu G, Nyarangi-Dix J, Simpfendörfer T, Schönberg G, Dimitrakopoulou-Strauss A, Freitag M, Duensing A, Grüllich C, Jäger D, Götz M, Grabe N, Schweiger MR, Pahernik S, Perner S, Herpel E, Roth W, Wieczorek K, Maier-Hein K, Debus J, Haberkorn U, Giesel F, Galle J, Hadaschik B, Schlemmer HP, Hohenfellner M, Bonekamp D, Sültmann H, Duensing S.

Sci Rep. 2018 Nov 12;8(1):16708. doi: 10.1038/s41598-018-35058-3.

7.

Absolute timing of the photoelectric effect.

Ossiander M, Riemensberger J, Neppl S, Mittermair M, Schäffer M, Duensing A, Wagner MS, Heider R, Wurzer M, Gerl M, Schnitzenbaumer M, Barth JV, Libisch F, Lemell C, Burgdörfer J, Feulner P, Kienberger R.

Nature. 2018 Sep;561(7723):374-377. doi: 10.1038/s41586-018-0503-6. Epub 2018 Sep 19.

PMID:
30232421
8.

FGF-2 is a driving force for chromosomal instability and a stromal factor associated with adverse clinico-pathological features in prostate cancer.

Pecqueux C, Arslan A, Heller M, Falkenstein M, Kaczorowski A, Tolstov Y, Sültmann H, Grüllich C, Herpel E, Duensing A, Kristiansen G, Hohenfellner M, Navone NM, Duensing S.

Urol Oncol. 2018 Aug;36(8):365.e15-365.e26. doi: 10.1016/j.urolonc.2018.05.020. Epub 2018 Jun 7.

PMID:
29887238
9.

Genomic features of renal cell carcinoma with venous tumor thrombus.

Warsow G, Hübschmann D, Kleinheinz K, Nientiedt C, Heller M, Van Coile L, Tolstov Y, Trennheuser L, Wieczorek K, Pecqueux C, Gasch C, Kuru T, Nyarangi-Dix J, Hatiboglu G, Teber D, Perner S, Stenzinger A, Roth W, Hadaschik B, Pahernik S, Jäger D, Grüllich C, Duensing A, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Duensing S.

Sci Rep. 2018 May 10;8(1):7477. doi: 10.1038/s41598-018-25544-z.

10.

The Impact of Hormonal Contraceptives on Breast Cancer Pathology.

Dorchak JA, Maria S, Guarinoni JL, Duensing A, Somiari S, Cavanaugh J, Deyarmin B, Hu H, Iida J, Shriver CD, Witt-Enderby PA.

Horm Cancer. 2018 Aug;9(4):240-253. doi: 10.1007/s12672-018-0332-y. Epub 2018 Apr 23.

11.

Ultrafast quantum control of ionization dynamics in krypton.

Hütten K, Mittermair M, Stock SO, Beerwerth R, Shirvanyan V, Riemensberger J, Duensing A, Heider R, Wagner MS, Guggenmos A, Fritzsche S, Kabachnik NM, Kienberger R, Bernhardt B.

Nat Commun. 2018 Feb 19;9(1):719. doi: 10.1038/s41467-018-03122-1.

12.

What's the FOX Got to Do with the KITten? Regulating the Lineage-Specific Transcriptional Landscape in GIST.

Lee DM, Duensing A.

Cancer Discov. 2018 Feb;8(2):146-149. doi: 10.1158/2159-8290.CD-17-1370.

13.

Overexpression of nuclear AR-V7 protein in primary prostate cancer is an independent negative prognostic marker in men with high-risk disease receiving adjuvant therapy.

Chen X, Bernemann C, Tolkach Y, Heller M, Nientiedt C, Falkenstein M, Herpel E, Jenzer M, Grüllich C, Jäger D, Sültmann H, Duensing A, Perner S, Cronauer MV, Stephan C, Debus J, Schrader AJ, Kristiansen G, Hohenfellner M, Duensing S.

Urol Oncol. 2018 Apr;36(4):161.e19-161.e30. doi: 10.1016/j.urolonc.2017.11.001. Epub 2017 Dec 1.

PMID:
29198908
14.

Mutations in BRCA2 and taxane resistance in prostate cancer.

Nientiedt C, Heller M, Endris V, Volckmar AL, Zschäbitz S, Tapia-Laliena MA, Duensing A, Jäger D, Schirmacher P, Sültmann H, Stenzinger A, Hohenfellner M, Grüllich C, Duensing S.

Sci Rep. 2017 Jul 4;7(1):4574. doi: 10.1038/s41598-017-04897-x.

15.

Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.

Rausch JL, Boichuk S, Ali AA, Patil SS, Liu L, Lee DM, Brown MF, Makielski KR, Liu Y, Taguchi T, Kuan SF, Duensing A.

Oncotarget. 2017 Jan 17;8(3):4471-4483. doi: 10.18632/oncotarget.13882.

16.

Spatial niche formation but not malignant progression is a driving force for intratumoural heterogeneity.

Hoefflin R, Lahrmann B, Warsow G, Hübschmann D, Spath C, Walter B, Chen X, Hofer L, Macher-Goeppinger S, Tolstov Y, Korzeniewski N, Duensing A, Grüllich C, Jäger D, Perner S, Schönberg G, Nyarangi-Dix J, Isaac S, Hatiboglu G, Teber D, Hadaschik B, Pahernik S, Roth W, Eils R, Schlesner M, Sültmann H, Hohenfellner M, Grabe N, Duensing S.

Nat Commun. 2016 Jun 13;7:ncomms11845. doi: 10.1038/ncomms11845.

17.

Targeting ETV1 in gastrointestinal stromal tumors: tripping the circuit breaker in GIST?

Duensing A.

Cancer Discov. 2015 Mar;5(3):231-3. doi: 10.1158/2159-8290.CD-15-0116.

18.

The DREAM complex in antitumor activity of imatinib mesylate in gastrointestinal stromal tumors.

DeCaprio JA, Duensing A.

Curr Opin Oncol. 2014 Jul;26(4):415-21. doi: 10.1097/CCO.0000000000000090. Review.

19.

Unbiased compound screening identifies unexpected drug sensitivities and novel treatment options for gastrointestinal stromal tumors.

Boichuk S, Lee DJ, Mehalek KR, Makielski KR, Wozniak A, Seneviratne DS, Korzeniewski N, Cuevas R, Parry JA, Brown MF, Zewe J, Taguchi T, Kuan SF, Schöffski P, Debiec-Rychter M, Duensing A.

Cancer Res. 2014 Feb 15;74(4):1200-13. doi: 10.1158/0008-5472.CAN-13-1955. Epub 2014 Jan 2.

20.

The DREAM complex mediates GIST cell quiescence and is a novel therapeutic target to enhance imatinib-induced apoptosis.

Boichuk S, Parry JA, Makielski KR, Litovchick L, Baron JL, Zewe JP, Wozniak A, Mehalek KR, Korzeniewski N, Seneviratne DS, Schöffski P, Debiec-Rychter M, DeCaprio JA, Duensing A.

Cancer Res. 2013 Aug 15;73(16):5120-9. doi: 10.1158/0008-5472.CAN-13-0579. Epub 2013 Jun 20.

21.

Closing in on accurate risk prediction and disease management for patients with operable GIST.

Duensing A.

Lancet Oncol. 2012 Mar;13(3):220-1. doi: 10.1016/S1470-2045(11)70344-8. Epub 2011 Dec 6. No abstract available.

PMID:
22153891
22.

Tripeptidyl Peptidase II Is Required for c-MYC-Induced Centriole Overduplication and a Novel Therapeutic Target in c-MYC-Associated Neoplasms.

Duensing S, Darr S, Cuevas R, Melquiot N, Brickner AG, Duensing A, Münger K.

Genes Cancer. 2010 Sep;1(9):883-92. doi: 10.1177/1947601910389605.

23.

Bortezomib: killing two birds with one stone in gastrointestinal stromal tumors.

Duensing S, Duensing A.

Oncotarget. 2010 May;1(1):6-8. Review. No abstract available.

24.

Synergistic induction of apoptosis by the Bcl-2 inhibitor ABT-737 and imatinib mesylate in gastrointestinal stromal tumor cells.

Reynoso D, Nolden LK, Yang D, Dumont SN, Conley AP, Dumont AG, Zhou K, Duensing A, Trent JC.

Mol Oncol. 2011 Feb;5(1):93-104. doi: 10.1016/j.molonc.2010.10.003. Epub 2010 Oct 16.

25.

Genomic instability and cancer: lessons learned from human papillomaviruses.

Korzeniewski N, Spardy N, Duensing A, Duensing S.

Cancer Lett. 2011 Jun 28;305(2):113-22. doi: 10.1016/j.canlet.2010.10.013. Epub 2010 Nov 13. Review.

26.

Daughter centriole elongation is controlled by proteolysis.

Korzeniewski N, Cuevas R, Duensing A, Duensing S.

Mol Biol Cell. 2010 Nov 15;21(22):3942-51. doi: 10.1091/mbc.E09-12-1049. Epub 2010 Sep 22.

27.

Centrosomes, polyploidy and cancer.

Duensing A, Duensing S.

Adv Exp Med Biol. 2010;676:93-103. Review.

PMID:
20687471
28.

A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.

Korzeniewski N, Wheeler S, Chatterjee P, Duensing A, Duensing S.

Mol Cancer. 2010 Jun 17;9:153. doi: 10.1186/1476-4598-9-153.

29.

Targeted therapies of gastrointestinal stromal tumors (GIST)--the next frontiers.

Duensing S, Duensing A.

Biochem Pharmacol. 2010 Sep 1;80(5):575-83. doi: 10.1016/j.bcp.2010.04.006. Epub 2010 Apr 10. Review.

PMID:
20385106
30.

Proapoptotic activity of bortezomib in gastrointestinal stromal tumor cells.

Bauer S, Parry JA, Mühlenberg T, Brown MF, Seneviratne D, Chatterjee P, Chin A, Rubin BP, Kuan SF, Fletcher JA, Duensing S, Duensing A.

Cancer Res. 2010 Jan 1;70(1):150-9. doi: 10.1158/0008-5472.CAN-09-1449. Epub 2009 Dec 22.

31.

Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin.

Spardy N, Covella K, Cha E, Hoskins EE, Wells SI, Duensing A, Duensing S.

Cancer Res. 2009 Sep 1;69(17):7022-9. doi: 10.1158/0008-5472.CAN-09-0925. Epub 2009 Aug 25.

32.

Cullin 1 functions as a centrosomal suppressor of centriole multiplication by regulating polo-like kinase 4 protein levels.

Korzeniewski N, Zheng L, Cuevas R, Parry J, Chatterjee P, Anderton B, Duensing A, Münger K, Duensing S.

Cancer Res. 2009 Aug 15;69(16):6668-75. doi: 10.1158/0008-5472.CAN-09-1284.

33.

Centrosome overduplication, chromosomal instability, and human papillomavirus oncoproteins.

Duensing A, Spardy N, Chatterjee P, Zheng L, Parry J, Cuevas R, Korzeniewski N, Duensing S.

Environ Mol Mutagen. 2009 Oct;50(8):741-7. doi: 10.1002/em.20478. Review.

PMID:
19326465
34.

HPV-16 E7 reveals a link between DNA replication stress, fanconi anemia D2 protein, and alternative lengthening of telomere-associated promyelocytic leukemia bodies.

Spardy N, Duensing A, Hoskins EE, Wells SI, Duensing S.

Cancer Res. 2008 Dec 1;68(23):9954-63. doi: 10.1158/0008-5472.CAN-08-0224.

35.

Imatinib mesylate induces quiescence in gastrointestinal stromal tumor cells through the CDH1-SKP2-p27Kip1 signaling axis.

Liu Y, Perdreau SA, Chatterjee P, Wang L, Kuan SF, Duensing A.

Cancer Res. 2008 Nov 1;68(21):9015-23. doi: 10.1158/0008-5472.CAN-08-1935.

36.

Soluble histone H2AX is induced by DNA replication stress and sensitizes cells to undergo apoptosis.

Liu Y, Parry JA, Chin A, Duensing S, Duensing A.

Mol Cancer. 2008 Jul 10;7:61. doi: 10.1186/1476-4598-7-61.

37.

ERCC1-XPF endonuclease facilitates DNA double-strand break repair.

Ahmad A, Robinson AR, Duensing A, van Drunen E, Beverloo HB, Weisberg DB, Hasty P, Hoeijmakers JH, Niedernhofer LJ.

Mol Cell Biol. 2008 Aug;28(16):5082-92. doi: 10.1128/MCB.00293-08. Epub 2008 Jun 9.

38.

Centrosome-mediated chromosomal instability and steroid hormones as co factors in human papillomavirus-associated cervical carcinogenesis: small viruses help to answer big questions.

Duensing A, Duensing S.

Adv Exp Med Biol. 2008;617:109-17. doi: 10.1007/978-0-387-69080-3_10. Review. No abstract available.

PMID:
18497035
39.
40.

The human papillomavirus type 16 E7 oncoprotein activates the Fanconi anemia (FA) pathway and causes accelerated chromosomal instability in FA cells.

Spardy N, Duensing A, Charles D, Haines N, Nakahara T, Lambert PF, Duensing S.

J Virol. 2007 Dec;81(23):13265-70. Epub 2007 Sep 26.

41.

KIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathway.

Bauer S, Duensing A, Demetri GD, Fletcher JA.

Oncogene. 2007 Nov 29;26(54):7560-8. Epub 2007 Jun 4.

PMID:
17546049
42.

Centriole overduplication through the concurrent formation of multiple daughter centrioles at single maternal templates.

Duensing A, Liu Y, Perdreau SA, Kleylein-Sohn J, Nigg EA, Duensing S.

Oncogene. 2007 Sep 20;26(43):6280-8. Epub 2007 Apr 16.

43.

Histone H2AX is a mediator of gastrointestinal stromal tumor cell apoptosis following treatment with imatinib mesylate.

Liu Y, Tseng M, Perdreau SA, Rossi F, Antonescu C, Besmer P, Fletcher JA, Duensing S, Duensing A.

Cancer Res. 2007 Mar 15;67(6):2685-92.

44.

p21(Waf1/Cip1) deficiency stimulates centriole overduplication.

Duensing A, Ghanem L, Steinman RA, Liu Y, Duensing S.

Cell Cycle. 2006 Dec;5(24):2899-902. Epub 2006 Dec 15.

45.

Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors.

Rubin BP, Duensing A.

Lab Invest. 2006 Oct;86(10):981-6. Epub 2006 Aug 21. Review.

46.

RNA polymerase II transcription is required for human papillomavirus type 16 E7- and hydroxyurea-induced centriole overduplication.

Duensing A, Liu Y, Spardy N, Bartoli K, Tseng M, Kwon JA, Teng X, Duensing S.

Oncogene. 2007 Jan 11;26(2):215-23. Epub 2006 Jul 3.

47.

A role of the mitotic spindle checkpoint in the cellular response to DNA replication stress.

Duensing A, Teng X, Liu Y, Tseng M, Spardy N, Duensing S.

J Cell Biochem. 2006 Oct 15;99(3):759-69.

48.

Viral carcinogenesis and genomic instability.

Münger K, Hayakawa H, Nguyen CL, Melquiot NV, Duensing A, Duensing S.

EXS. 2006;(96):179-99. Review.

PMID:
16383019
49.

Cyclin-dependent kinase 2 is dispensable for normal centrosome duplication but required for oncogene-induced centrosome overduplication.

Duensing A, Liu Y, Tseng M, Malumbres M, Barbacid M, Duensing S.

Oncogene. 2006 May 11;25(20):2943-9.

50.

Guilt by association? p53 and the development of aneuploidy in cancer.

Duensing A, Duensing S.

Biochem Biophys Res Commun. 2005 Jun 10;331(3):694-700. Review.

PMID:
15865924

Supplemental Content

Loading ...
Support Center